Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Value-Added Medicines Regulation Europe

Consensus Is Essential To Find Best Value-Added Path

Insists Medicines For Europe’s Value Added Medicines Chair Arun Narayan

  • Interviews

Executive Summary

Finding a consensus across European stakeholders on how best to recognize and reward the benefits of value added medicines is key to the sector’s success, says Arun Narayan – chairman of the value added medicines sector group at Medicines for Europe and also head of global portfolio strategy and head of European business operations at Mylan – in an exclusive interview with Generics Bulletin.

Table

View full table

Topics

Related Companies

Tags:
Value-Added Medicines Regulation Europe
Latest Headlines

EU Urban Wastewater Directive Update ‘Unfairly Targets Pharmaceutical Industry’

Amgen Kicks Off Pembrolizumab Program As It Delivers Q1 Results

Lupin Enters Canadian Biosimilars Market With Etanercept

Are Jubilant Pharmova’s US Plant Closure, FDA Observations At Canada Unit A Concern?

See All
UsernamePublicRestriction

Register

GB149403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By